Literature DB >> 15591121

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.

M E Christine Lutsiak1, Roshanak T Semnani, Roberto De Pascalis, Syed V S Kashmiri, Jeffrey Schlom, Helen Sabzevari.   

Abstract

Regulatory T cells (T(REGs)) control the key aspects of tolerance and play a role in the lack of antitumor immune responses. Cyclophosphamide (CY) is a chemotherapeutic agent with a dose-dependent, bimodal effect on the immune system. Although a previous study demonstrated that CY reduces the number of T(REGs), the mechanism involved in this process has yet to be defined. In this report, it is established that low-dose CY not only decreases cell number but leads to decreased functionality of T(REGs). CY treatment enhances apoptosis and decreases homeostatic proliferation of these cells. Expression of GITR and FoxP3, which are involved in the suppressive activity of T(REGs), is down-regulated after CY administration, though the level of expression varies depending on the time studied. This is the first report demonstrating that CY, in addition to decreasing cell number, inhibits the suppressive capability of T(REGs). The relevance of the loss of suppressor functionality and the changes in gene expression are further discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15591121     DOI: 10.1182/blood-2004-06-2410

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  317 in total

Review 1.  L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review.

Authors:  Wenjie Xia; Jie Wang; Youtao Xu; Feng Jiang; Lin Xu
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects.

Authors:  Eleonora Reginato; Peter Wolf; Michael R Hamblin
Journal:  World J Immunol       Date:  2014-03-27

Review 3.  Anti-HER2 vaccines: new prospects for breast cancer therapy.

Authors:  Maha Zohra Ladjemi; William Jacot; Thierry Chardès; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  Cancer Immunol Immunother       Date:  2010-06-08       Impact factor: 6.968

Review 4.  Metronomic chemotherapy: new rationale for new directions.

Authors:  Eddy Pasquier; Maria Kavallaris; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2010-06-08       Impact factor: 66.675

Review 5.  Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy.

Authors:  Enrico Proietti; Federica Moschella; Imerio Capone; Filippo Belardelli
Journal:  Mol Oncol       Date:  2011-12-03       Impact factor: 6.603

6.  Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models.

Authors:  Yingjen Jeffrey Wu; Leslie L Muldoon; Dana Thomas Dickey; Seth J Lewin; Csanad G Varallyay; Edward A Neuwelt
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

Review 7.  Chemoimmunotherapy: reengineering tumor immunity.

Authors:  Gang Chen; Leisha A Emens
Journal:  Cancer Immunol Immunother       Date:  2013-02-07       Impact factor: 6.968

8.  Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.

Authors:  Madhav D Sharma; Babak Baban; Phillip Chandler; De-Yan Hou; Nagendra Singh; Hideo Yagita; Miyuki Azuma; Bruce R Blazar; Andrew L Mellor; David H Munn
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 9.  Chemotherapeutic targeting of cancer-induced immunosuppressive cells.

Authors:  Darya Alizadeh; Nicolas Larmonier
Journal:  Cancer Res       Date:  2014-04-28       Impact factor: 12.701

Review 10.  Enhancing efficacy of therapeutic vaccinations by combination with other modalities.

Authors:  James L Gulley; Ravi A Madan; Philip M Arlen
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.